A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Exclusion Criteria

• •Before surgery:
• •History in the past 10 years of malignancy, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ
• •History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
• •History of abnormal laboratory results \>=2.5\*upper limit of normal (ULN)
• •History of peripheral neuropathy
• •A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses
• •Prior medical history of bunionectomy or other foot surgery on the index foot
• •History of peptic ulcer disease, or intolerance or unwillingness to receive ibuprofen
• •After surgery:
• •Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery